Many scientific organizations have published guidelines and recommendations concerning active and latent TB infection.[4–7] However, latent TB infection reactivation still occurs in patients with IBD treated with anti-TNF-alpha agents despite compliance with recommended preventive measures.[8] Furthermore, therapeutic strategies for patients with IBD who develop anti-TNF-alpha agent-associated active TB infection have not yet been established. This evidence concerns the gene TNF and inflammatory bowel disease.